Match tier
Listed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
P
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Phuc Tran's research has focused on the development of novel therapeutic agents and understanding disease mechanisms. Their work includes investigating proteolysis-targeting chimeras (PROTACs) and their role in targeted protein degradation, as evidenced by a publication on 3-aminophthalic acid as a cereblon ligand for O’PROTACs. Tran has also studied inhibitors for Type I RET and RET gatekeeper mutant kinases, exploring their novel kinase binding poses. Further research has examined the role of proteins like Mi-2β in immune evasion in melanoma by activating EZH2 methylation. Additionally, Tran has contributed to studies on the delivery of oligonucleotides using lipid conjugation and the modulator effects of pegylated hemoglobin on inflammation and vaso-occlusion in sickle cell models. Their scholarship metrics include an h-index of 6 with 12 publications and 169 citations.
Metrics
- h-index: 6
- Publications: 9
- Citations: 178
Positions
-
Undergraduate ResearcherUniversity of Alberta Pharmacology ORCID
-
Undergraduate Researcher publications 2020–2025University of Arkansas for Medical Sciences ORCID
Selected Publications
-
Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor (2025)
-
CD36-mediated endocytosis of proteolysis-targeting chimeras (2025)
-
Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation (2024)
-
An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L (2023)
-
Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas (2023)
-
Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome (2022)
-
3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC (2022)
-
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose (2022)
-
Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology (2021)
-
Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors (2021)
-
Mi-2β-targeted inhibition induces immunotherapy response in melanoma (2020)
Collaboration Network
Top Collaborators
Hongyu Li
The University of Texas at San Antonio Health Science Center (US)
9 shared publications
- CD36-mediated endocytosis of proteolysis-targeting chimeras
- Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome
- 3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas
Showing 5 of 9 shared publications
Yuet‐Kin Leung
University of Arkansas for Medical Sciences
4 shared publications
In database
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
Brendan Frett
University of Arkansas for Medical Sciences
4 shared publications
In database
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
Wei Yan
The University of Texas at San Antonio Health Science Center (US)
4 shared publications
- CD36-mediated endocytosis of proteolysis-targeting chimeras
- 3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Anupreet Kharbanda
University of Arkansas for Medical Sciences
3 shared publications
In database
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
Lingtian Zhang
University of Arkansas for Medical Sciences (US)
3 shared publications
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
Xiuqi Wang
University of Arkansas for Medical Sciences
3 shared publications
In database
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Licheng Yao
Tsinghua University (CN)
2 shared publications
- Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation
- Mi-2β-targeted inhibition induces immunotherapy response in melanoma
Xingyu Lin
2 shared publications
- Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation
- Mi-2β-targeted inhibition induces immunotherapy response in melanoma
James Hagman
National Jewish Health (US)
2 shared publications
- Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation
- Mi-2β-targeted inhibition induces immunotherapy response in melanoma
Jingwei Shao
Chongqing University of Arts and Sciences (CN)
2 shared publications
- Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation
- Mi-2β-targeted inhibition induces immunotherapy response in melanoma
Meng Cao
Nanjing University of Chinese Medicine (CN)
2 shared publications
- Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation
- Mi-2β-targeted inhibition induces immunotherapy response in melanoma
Colin R. Goding
University of Oxford (GB)
2 shared publications
- Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation
- Mi-2β-targeted inhibition induces immunotherapy response in melanoma
Xuebin Liao
King Center (US)
2 shared publications
- Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation
- Mi-2β-targeted inhibition induces immunotherapy response in melanoma
Hongyu Li
University of Arkansas for Medical Sciences (US)
2 shared publications
- Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation
- Mi-2β-targeted inhibition induces immunotherapy response in melanoma
Similar Researchers
Based on overlapping research topics
Benjamin Davis
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Disease Mechanisms Research
Metabolism and Genetic Disorders
LF Hutchins
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Disease Mechanisms Research
Metabolism and Genetic Disorders
Anita Naushir Akbar Ali
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Disease Mechanisms Research
Pharmacological Effects and Toxicity Studies
Leanne Whiteside Mansell
University of Arkansas for Medical Sciences
Disease Mechanisms Research
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies
Jingwei Shao
University of Arkansas for Medical Sciences
Protein Degradation and Inhibitors
Cancer-related molecular mechanisms research
Metabolism and Genetic Disorders
Matthew Deneke
University of Arkansas for Medical Sciences
Protein Degradation and Inhibitors
Disease Mechanisms Research
Pharmacological Effects and Toxicity Studies